^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:Darzalex (daratumumab) (CD38 inhibitor) +
    thalidomide (TNF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    PRNewswire
    Title:

    Janssen Announces Health Canada Approval of DARZALEX Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

    Published date:
    12/22/2020
    Excerpt:
    The Janssen Pharmaceutical Companies of Johnson & Johnson announce that Health Canada has approved DARZALEX (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).
    Secondary therapy:
    bortezomib; dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    05/20/2016
    Excerpt:
    Darzalex is indicated...in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
    Secondary therapy:
    bortezomib + dexamethasone; prednisone + melphalan